HIV therapy by a combination of broadly neutralizing antibodies in humanized mice by Klein, Florian et al.
HIV therapy by a combination of broadly neutralizing antibodies
in humanized mice
Florian Klein1, Ariel Halper-Stromberg#1, Joshua A. Horwitz#1, Henning Gruell1,4, Johannes
F. Scheid1,5, Stylianos Bournazos2, Hugo Mouquet1, Linda A. Spatz1,6, Ron Diskin7,
Alexander Abadir1, Trinity Zang9, Marcus Dorner3, Eva Billerbeck3, Rachael N. Labitt3,
Christian Gaebler1,8, Paola Marcovecchio7, Reha-Baris Incesu1, Thomas R. Eisenreich1,
Paul D. Bieniasz9,11, Michael S. Seaman10, Pamela J. Bjorkman7,11, Jeffrey V. Ravetch2,
Alexander Ploss3, and Michel C. Nussenzweig1,11,@
1Laboratory of Molecular Immunology, The Rockefeller University; New York, New York 10065;
United States
2Laboratory of Molecular Genetics and Immunology, The Rockefeller University; New York, New
York 10065; United States
3Laboratory of Virology and Infectious Diseases, The Rockefeller University; New York, New York
10065; United States
4Medizinische Fakultät, Westfälische Wilhelms-Universität Münster; D-48149 Münster; Germany
5Charite Universitätsmedizin; D-10117 Berlin; Germany
6Department of Microbiology and Immunology, Sophie Davis School of Biomedical Education,
The City College of New York; New York, New York 10031; United States
7Division of Biology, California Institute of Technology; Pasadena, CA 91125; United States
8Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden; D-01307 Dresden;
Germany
9Aaron Diamond AIDS Research Center, Laboratory of Retrovirology, The Rockefeller University;
New York, New York 10065; United States
10Beth Israel Deaconess Med. Ctr.; Boston, MA 02215; United States
11Howard Hughes Medical Institute
#
 These authors contributed equally to this work.
Summary
Human antibodies to HIV-1 can neutralize a broad range of viral isolates in vitro and protect non-
human primates against infection1,2. Previous work showed that antibodies exert selective
pressure on the virus but escape variants emerge within a short period of time3,4. However, these
experiments were performed before the recent discovery of more potent anti-HIV-1 antibodies and
their improvement by structure-based design5-9. Here we re-examine passive antibody transfer as a
therapeutic modality in HIV-1-infected humanized mice (hu-mice). Although HIV-1 can escape
@Correspondence should be addressed to: nussen@rockefeller.edu.
Author Contributions: F.K., A.H.-S., J.A.H. planned and performed experiments and wrote the manuscript. H.G., J.F.H., S.B., H.M.,
L.A.S., R.D., A.A., T.Z., M.D., E.B., R.N.L., C.G., P.M., R.-B.I., T.R.E. and M.S. performed experiments. P.D.B., P.J.B., J.V.R., A.P.
provided reagents, advise and edited the manuscript. M.C.N. planned experiments and wrote the manuscript.
Author information: The authors declare no competing financial interests.
NIH Public Access
Author Manuscript
Nature. Author manuscript; available in PMC 2013 October 28.
Published in final edited form as:
Nature. 2012 December 6; 492(7427): . doi:10.1038/nature11604.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
from antibody monotherapy, combinations of broadly neutralizing antibodies (bNAbs) can
effectively control HIV-1 infection and suppress viral load to levels below detection. Moreover, in
contrast to antiretroviral therapy (ART)10-12, the longer half-life of antibodies led to viremic
control for an average of 60 days after cessation of therapy. Thus, combinations of potent
monoclonal antibodies can effectively control HIV-1 replication in hu-mice, and should be re-
examined as a therapeutic modality in HIV-1-infected individuals.
Treatment of HIV-1 infection was ineffective until antiretroviral drugs were applied in
combination permitting sustained suppression of viremia13,14. Despite this resounding
success, the burden of daily medication, side effects, and resistance to antiretroviral drugs
necessitate a continuing search for additional complementary therapeutic modalities15.
To examine the potential of recently discovered antibodies to effectively control HIV-1
infection, we used non-obese diabetic (NOD) mice that carry targeted disruptions of the
recombinase activating gene 1 (Rag1−/−) and interleukin receptor common gamma chain
(IL2RγNULL) reconstituted with human fetal liver-derived CD34+ hematopoietic stem
cells16,17. Hu-mice were preferred to nonhuman primates for these experiments because the
latter produce anti-human antibodies that alter the bioavailability of the injected human
antibodies after only one to two weeks.
Hu-mice were analyzed for engraftment (Supplementary Fig. 1) and infected
intraperitoneally (i.p) with a CCR5-tropic HIV-1 isolate (NL4-3 carrying a YU2 envelope;
HIV-1YU2)18. Viral load in serum was determined by quantitative RT-PCR with a limit of
detection of 800 copiesiml (Supplementary Fig. 2). Viremia was established (geometric
mean of 1.06×105 copies/ml) by 14-20 days, and was stable for 60 days before decreasing to
a geometric mean of 1.9×104 copies/ml at 120 days after infection (Fig. 1a). Persistent
viremia was associated with progressive reduction in CD4+ T cells as measured by
decreasing CD4+/CD8+ T cell ratios (Supplementary Fig. 3).
To confirm that HIV-1YU2 infection in hu-mice is associated with viral diversification19 we
cloned and sequenced 69 gp120 envelopes from 10 infected mice (Fig. 1a). After accounting
for randomly introduced PCR errors (Supplementary Fig. 4a and b), we observed an average
of 3.2 nucleotide substitutions per gp120 sequence, corresponding to a substitution rate of
2.2×10−3/bp (Supplementary Fig. 4b and c). We conclude that HIV-1YU2 infection is well
established by 14-20 days in hu-mice, it persists for several months, and the virus mutates
generating viral swarms18,19.
To examine the effects of bNAbs on established HIV-1 infection, we treated groups of 5-9
(3-8 analyzed) mice with antibody monotherapy using five different bNAbs. The antibodies
were selected based on their potency and breadth in in vitro neutralization assays and
because they target different epitopes. 45-46G54W is the most potent anti-CD4 binding site
(CD4bs) antibody reported to date5, PG16 targets the V1/V2 loop region8,20, PGT128 is a
glycan-dependent anti-V3 loop antibody7 and 10-1074 is a more potent variant of
PGT1217,21 that has no measurable affinity for protein-free complex-type N-glycans in
microarrays21. 3BC176 recognizes a conformational, yet to be defined epitope, and
neutralizes HIV-1 strains that are resistant to potent CD4bs-antibodies22. Mice were treated
subcutaneously with 0.5 mg of antibody/mouse (≅ 20 mg/kg) either once or twice a week
based on the antibodies’ half-lives in mice, which varied from 0.7 to 6.3 days
(Supplementary Fig. 5).
6-7 days after initiation of therapy, mice treated with PGT128 or 10-1074 showed an
average decrease of 1.1 log10 (p≤0.05) and 1.5 log10 (p≤0.01) HIV-1 RNA copies/ml,
respectively (Fig. 1b and c, Supplementary Table 1). The results for PG16 and 45-46G54W
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were variable, with an average decrease of 0.23 log10 and 0.56 log10 copies/ml (Fig. 1b and
c, and Supplementary Table 1), while no effect was detected for 3BC176. However, with the
exception of one mouse receiving 10-1074, viremia rebounded after 14-16 days and no
significant differences between treated and control groups were detected thereafter (Fig. 1b
and c). We conclude that monotherapy with PG16, 45-46G54W, PGT128 or 10-1074 results
in an only transient decrease in the viral load in hu-mice infected with HIV-1YU2.
To determine whether viral escape from monoclonal antibody therapy is linked to specific
mutations we cloned and sequenced gp120 from 3-6 infected mice in each therapy group
before (Supplementary Fig. 6) and after (Supplementary Fig. 7) viral rebound. In all cases,
viral rebound was associated with recurring mutations (defined as substitutions within a
range of 3 amino acids in a majority of gp120 clones in more than one mouse) in residues
that map to the antibody target sites (Fig. 1d, Supplementary Fig. 7, Supplementary Table
2b). For example, escape from 45-46G54W, was linked to mutations in residues 276-281 or
458, 459, which are located in the CD4bs23. Likewise, escape from PG16 was associated
with mutations at residues 160 or 162, which correspond to the potential N-linked
glycosylation site (PNGS) in the V1/V2 loop8,20. Escape from PGT128 and 10-1074 was
associated with mutations at residues 332 or 334, both of which abrogate the same PNGS
(Fig. 1d; Supplementary Fig. 7, Supplementary Table 2b).
To verify that the putative escape mutations rendered HIV-1YU2 resistant to the respective
antibodies, we produced selected HIV-1YU2 pseudoviruses carrying the mutations and tested
them in neutralization assays in vitro. Recurrent mutations associated with escape were
always associated with specific resistance to their respective antibodies (Supplementary Fig.
8). Passenger mutations, defined as occurring in only a single mouse, or in multiple mice but
in fewer than 50% of gp120 sequences in those mice, had no apparent effect on viral
sensitivity to the antibodies (Supplementary Fig. 8).
Although escape mutations were associated with antibody-targeted epitopes, some gp120
residues appeared to tolerate multiple alternative amino acid substitutions, while others were
more restricted. For example, in hu-mice treated with 45-46G54W N279 mutated to H, K, or
I, but A281, only became T (Fig. 1d; Supplementary Table 2b). Escape from PGT128, was
associated with replacement of N332 with K, S, T, or Y, while it became K in 51 out of 53
sequences from 4 hu-mice treated with 10-1074 (Fig. 1d; Supplementary Fig. 7,
Supplementary Table 2b). Consistent with this observation, N332K is resistant to both
PGT128 and 10-1074, while N332Y is resistant to PGT128 but remains sensitive to high
concentrations of 10-1074 (Supplementary Fig. 8).
Since the selected bNAbs target distinct epitopes on the HIV-1 spike, we asked whether
treatment with a combination of three (tri-mix = 3BC176, PG16, 45-46G54W) or five (penta-
mix = 3BC176, PG16, 45-46G54W, PGT128, and 10-1074) would alter the course of
infection (Fig. 2, Supplementary Table 1). These combinations neutralize all but 2 (tri-mix
98.3%) and 1 (penta-mix 99.2%) of 119 mostly Tier 2 and 3 viruses from multiple clades
with an IC80 (geometric mean) of 0.121 μg/ml and 0.046 μg/ml for tri-mix and penta-mix,
respectively (Supplementary Fig. 9).
A decline in the initial viral load was seen in 10 out of 11 tri-mix treated mice, but 7
rebounded to pre-treatment levels (Fig. 2a, Supplementary Table 1c, Supplementary Fig.
10). In contrast to monotherapy where mice almost never controlled viremia beyond 2
weeks of therapy, the tri-mix led to prolonged and effective HIV-1 control in 3 of 12
animals. In 2 of these mice viral load rebounded 20–40 days after cessation of therapy at a
time when the YU2 gp120-reactive antibody concentration in serum decreased to a level
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below detection (Fig. 3a). In the third mouse (ID21), viremia was detected but remained low
even in the absence of therapy for 60 days.
Sequences obtained from mice that experienced viral rebound while on tri-mix therapy
showed a combination of the mutations found in the PG16 and 45-46G54W monotherapy
groups (Fig. 1d, 2b and c, Supplementary Table 2b, 3a). We verified that these mutations
rendered HIV-1YU2 resistant to PG16 and 45-46G54W by producing the corresponding
mutant pseudoviruses and testing them in neutralization assays in vitro (Supplementary Fig.
8). The pseudoviruses were not resistant to 3BC176 confirming that this antibody did not
exert selective pressure on HIV-1YU2 and therefore just 2 of the 3 antibodies in the tri-mix
were efficacious.
In contrast, sequences obtained from the mice that exhibited sustained viral control and
rebounded after cessation of therapy either lacked any bNAb-associated mutation, or had a
mutation mapped to the 45-46G54W (K282R) or PG16 (N162P) target site, but not both (Fig.
3 b, Supplementary Table 3a). In these mice, rebound viremia only occurred after YU2
gp120-reactive antibody levels decreased to below detection suggesting that the viruses that
emerged were latent and remained susceptible to the tri-mix.
All 13 mice treated with the penta-mix showed a decrease in viral load 6-7 days after
initiation of therapy (Fig. 2d, Supplementary Table 1d). However, in contrast to
monotherapy and the tri-mix, all of the penta-mix treated mice remained below baseline
during the entire treatment course (Fig. 2d, Supplementary Table 1d, Supplementary Fig.
10). Of the 13 mice, 11 had viral loads below or near the limit of detection. The two mice
with the slowest reduction in viral load during treatment showed signs of severe graft versus
host disease (GVHD). We conclude that penta-mix therapy reduces the viral load to levels
below detection for up to 60 days in HIV-1YU2-infected hu-mice.
Penta-mix therapy was discontinued after 31–60 days and the mice were monitored for an
additional 100 days (Fig. 3c). In 7 out of 8 mice that survived, viremia only rebounded after
an average of 60 days (Fig. 3c). In contrast, mice treated with ART rebound after 10 days
following discontinuation of therapy10. Viral rebound in penta-mix-treated mice was always
correlated with decreased levels of the administered antibodies (Fig. 3c). Only one tri-
(ID21) and one penta-mix (ID129) mouse failed to rebound. To determine their ability to
support HIV-1 infection, these mice were re-infected with HIV-1YU2 (57.5 ng p24) and
measured for viral load 2 weeks later. One of the two mice was infected but only at very low
levels compared to the initial infection (Supplementary Fig. 11). Therefore prolonged
control was primarily due to the long half-life of the injected antibodies.
We attempted to clone gp120 sequences from the plasma and cell-associated RNA of all
penta-mix mice. Although we succeeded in obtaining sequences from 3 mice during the
treatment period, every sequenced clone had at least one in-frame stop codon, all of which
were consistent with signature APOBEC3G/F mutations (Supplementary Fig. 12,
Supplementary Table 3b). In contrast, 27 of 28 gp120 sequences from viruses cloned after
therapy was stopped and viral load rebounded did not have stop codons (Fig. 3d,
Supplementary Table 3b). Furthermore, viruses that rebounded carried no or only one
signature resistance mutation and remained susceptible to the penta-mix since viremia was
controlled by re-treatment (Fig. 3e). Therefore, hu-mice treated with the penta-mix were
unable to escape antibody pressure by way of envelope mutations, but the virus remained
latent throughout the treatment period in at least 7 out of 8 mice.
HIV-1 infection in hu-mice differs from HIV-1 infection in humans in a number of
important respects including a lower viral load, and a near absence of antibody-mediated
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immune responses, and therefore there is no pre-existing selective pressure on the
envelope18 (Supplementary Fig. 13).
Previous antibody therapy experiments in hu-mice and humans concluded that treatment
with combinations of antibodies had only limited effects against established HIV-1
infection4,24,25. However, the bNAbs used in those experiments (i.e. in mice b12, 2G12,
2F5; in humans 2G12, 4E10, 2F5) were orders of magnitude less potent than the ones used
in this study. The difference in potency and the extended combination of broadly
neutralizing antibodies is likely to account for the differences between our findings and
earlier work.
Combination antibody therapy resembles antiretroviral or antimicrobial or anti-tumor
combined therapy, in that escape requires the improbable appearance of multiple
simultaneous mutations. However, antibodies differ from other therapeutic modalities for
HIV in several respects. First, they can neutralize the pathogen directly; second, they have
the potential to clear the virus and infected cells through engagement of innate effector
responses26; third, immune complexes produced by the passively transferred antibodies may
enhance immunity to HIV-127 and fourth antibodies have far longer half-lives than currently
used antiretroviral drugs. Finally, anti-HIV-1 antibodies can be stably expressed in
mammalian hosts for many months using adeno-associated viruses and therefore the
potential exists to further prolong their bioavailability28,29. Although we have not combined
antibodies and small molecule antiretroviral drugs, we speculate that such combinations may
be especially effective because antibodies add a new modality to existing therapies. In
addition, a combination of highly potent antibodies may be effective in suppressing viremia
in individuals who do not tolerate anti-HIV medication.
This study establishes the principle that broadly neutralizing antibodies can suppress HIV-1
viremia to levels that are below detection in hu-mice for prolonged periods of time. Their
efficacy as therapeutics and their long-term effects on HIV-1 infection in humans can only
be evaluated in clinical trials.
Methods
Mice
NOD Rag1−/− IL2RγNULL (NOD.Cg-Ragltm1Mom Il2rgtm1Wjl/SzJ) mice were purchased
from The Jackson Laboratory and bred and maintained at the Comparative Bioscience
Center of the Rockefeller University according to guidelines established by the Institutional
Animal Committee. All experiments were performed with authorization from the
Institutional Review Board and the IACUC at the Rockefeller University.
Isolation of human hematopoietic stem cells (HSCs) and generation of humanized mice
Human fetal livers were procured from Advanced Bioscience Resources (ABR), Inc
(Alameda) or the Human Fetal Tissue Repository (HFTR, Bronx, Ny). HSCs were isolated
as previously described31. Briefly, human fetal liver was homogenized and incubated in
digestion medium (HBSS with 0.1% collagenase IV (Sigma-Aldrich), 40mM HEPES, 2mM
CaCl2 and 2U/ml DNAse I (Roche)) for 30 min at 37°C. Human CD34+ HSCs were isolated
using a CD34+ HSC isolation kit (Stem Cell Technologies, Inc.) according to the
manufacturers’ instructions. 1-5 day old NOD Rag1−/− IL2RγNULL (NRG) mice were
irradiated with 100 cGy and 1.5-2×105 human CD34+ HSCs were injected intrahepatically 6
h after irradiation.
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Flow cytometry
Flow cytometry was used to assess human hematopoiectic engraftment in mouse
xenorecipients and to determine CD4+ to CD8+ T cell ratios. To this end, 200 μl of whole
blood was collected from the superficial temporal vein of hu-mice and density gradient
centrifugation (Ficoll-Paque™) was performed. Isolated peripheral blood mononuclear cells
(PBMCs) were stained with anti-mouse CD45-PeCy7 (BioLegend), anti-human CD3-
Pacific-Blue (BD Pharmingen), CD4-PE (BD), CD8-FITC (BD), CD16-Alexa700 (BD
Pharmingen), CD19-APC (BD Pharmingen) and CD45-Pacific-Orange (Invitrogen) for 25
min at 4°C. Cells were washed and then fixed in 4% paraformaldehyde. To determine
absolute numbers of CD4+ T cells in peripheral blood AccuCheck Counting Beads
(Molecular Probes®) were added to the samples. FACS analysis was performed using a BD
LSRFortessa cell analyzer (BD Biosciences) and data was analyzed using FlowJo Software
(Tree Star).
HIV-1YU2 virus production
HIV-1YU2 was produced as previously described32 and levels of p24 in viral supernatant
determined using Alliance HIV-1 p24 ANTIGEN ELISA Kit (PerkinElmer) according to the
manufacturer’s instructions.
Quantitative reverse-transcriptase PCR assay
Blood was obtained from the superficial temporal vein and collected into EDTA-Microtubes
(Sarstedt). After centrifugation, RNA was extracted from 100μl EDTA-plasma using a
Qiagen MinElute Virus Spin Kit (Qiagen) and eluted in 50μl (2× 25μl elutions) RNAse free
water (Qiagen). RNA samples were analyzed for HIV-1 RNA in a 50μl reaction mix using
the 1× TaqMan® RT-PCR Mix, the 1× TaqMan® RT Enzyme Mix (TaqMan® RNA-to-
Ct™ 1-Step kit, Applied Biosystems) and primers targeting a highly region conserved
within the HIV-1 5′ long terminal repeat (FW 5′-GCCTCAATAAAGCTTGCCTTGA-3′;
Rev 5′-GGCGCCACTGCTAGAGATTTT-3′)30. The internal probe (5′-
AAGTAGTGTGTGC-CCGTCTGTTRTKTGACT-3′)30 contained a 5′ 6-
carboxyfluorescein reporter and an internal/3′ ZEN-Iowa Black® FQ double-quencher
(Integrated DNA Technologies, Inc.). As standard references (standard #1 and #2) two
different dilutions from a single HIV-1NL4-3/BaL preparation were generated and quantified
in duplicates by the Roche COBAS® TaqMan® HIV-1 Test, v.2.0 (Rolf Kaiser, University
of Cologne, Germany). These reference aliquots were stored at −80°C and always extracted
in parallel with mouse plasma samples. To generate a reference curve standard #1 was five-
fold serially diluted from 173,500,000 to 4 HIV-1 RNA copies/ml (Supplementary Fig. 2).
Standard #2 containing 2,600,000 copies/ml was used as a control for experimental
variation: all sample Ct-values in a given experiment were adjusted by the difference
between the experimental Ct-value for standard #2 and its expected Ct-value calculated
using each experiment’s standard curve (generated using standard #1). Final viral load
values were calculated using the control-adjusted Ct for each sample.
qRT-PCR assay, limit of detection
The lower limit of detection (LOD) for the assay used in this study was found at 800 copies/
ml. HIV-1 culture supernatant of known RNA copy number was serially diluted two-fold to
concentrations between 1600 and 200 copies/ml (corresponding to 64 to 8 copies per 20ul
RNA extract). Each dilution was independently extracted and assayed at n=4 per
experiment. The presence of a cycle threshold value for a given PCR reaction was scored as
a detection event. Detection scores accumulated from five identical experiments were
subjected to probit analysis, and the 85% LOD was found at 800 copies/ml for undiluted
RNA extract (corresponding to 32 copies/PCR reaction). For RNA diluted five-fold in
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deionized nuclease free water, the 85% LOD was 640 copies/ml (corresponding to 5 copies/
PCR reaction).
Antibody production, t1/2 estimation and administration
Antibodies were generated as previously described5,33,34. Briefly, HEK 293T/17 or HEK
293-6E cells were transiently transfected with equal amounts of immunoglobulin heavy and
light chain expression vectors. After supernatant was harvested, purified IgG was obtained
using HiTrap rProtein A FF columns (GE Healthcare) or Protein G sepharose 4 Fast Flow
(GE Healthcare). Sterile filtration was performed for all antibodies shortly before injection
by using Ultrafree-CL Centrifugal Filters (0.22 μm, Millipore). Antibody t1/2 was calculated
by ln(2)/k where k is 1st order reaction rate constant and calculated as a slope of ln(antibody
concentration) vs. time. Based on t1/2 of bNAbs HIV-1YU2-infected hu-mice were treated
with 0.5 mg of each antibody injected subcutaneously once (3BC176) or twice (PG16,
45-46G54W, PGT128, 10-1074)/week. The tri-mix was composed of 3BC176, PG16 and
45-46G54W while the penta-mix included all five given antibodies. To determine antibody
t1/2, 0.5 mg of antibody was administered intravenously by retro-orbital injection
(Supplementary Fig. 5).
ELISA
Costar® 96-Well EIA/RIA Stripwell™ Plates were coated overnight with YU2 gp120 or
goat Anti-Human IgG specific for Fcγ fragment at 250 and 150 ng/well, respectively. Plates
were washed 3 × with distilled water and blocked for 1 h with PBST (0.1% Tween-20)
containing 2% BSA and 1 μM EDTA. Standard IgG1 kappa (Sigma-Aldrich) and 10-1074
were used in duplicates as standard antibodies for quantifying total IgG and YU2 gp120-
specific IgGs, respectively. After washing the plate, mouse plasma was applied in 1:3 serial
dilutions with a 1:10 or 1:20 starting dilution and incubated for 2 h followed by washing the
plate and 1 h incubation with Peroxidase-conjugated Goat Anti-human IgG (Jackson
ImmunoResearch). Plates were washed and developed using ABTS single solution
(Invitrogen). Optical density was measured at 405nm and IgG concentration determined by
correlation to the standard curve of the reference antibodies. Of note, YU2 gp120 does not
react with PG16 or 3BC176 and therefore these mAbs are not detected by the YU2 gp120
ELISA.
Neutralization
Single antibodies and tri- and penta-mix were tested against a panel of HIV-1 envelope-
pseudoviruses as previously described6,35,36 or HIV-1YU2-mutant variants. Briefly,
envelope-pseudoviruses were incubated with 5-fold serial dilutions of single antibodies or
tri- and penta-mix samples and applied to TZM.bl cells that carry a luciferase-reporter gene.
After 48 h cells were lysed and luminescence was measured. IC50 and IC80 reflect single
antibody concentrations that caused a reduction in relative luminescence units (RLU) by
50% and 80%, respectively.
cDNA synthesis
Viral RNA was extracted as described above and subjected to first-strand cDNA synthesis
using the SuperScript III reverse transcriptase kit (Invitrogen Life Technologies, Grand
Island, Ny). For extraction of cellular RNA an RNA extraction kit was used (Qiagen). Sense
and anti-sense primers used for cDNA synthesis were 5′-
GGCTTAGGCATCTCCTATGGCAGGAAGAA-3′ and 5′-
GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-3′, respectively.
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PCR amplification and cloning
PCR amplifications were performed in ThermoGrid 96-well plates (Denville Scientific)
using either the Clontech Advantage 2 PCR System (BD) or the Expand High Fidelity PCR
System (Roche). All PCR amplifications were performed in a 50 μl reaction mix. The
primers used for the first round of PCR were 5′-
GGCTTAGGCATCTCCTATGGCAGGAAGAA-3′ and 5′-
GGTGTGTAGTTCTGCCAATCAGGGAAGWAGCCTTGTG-3′. Primers for the second-
round PCR were 5′-TAGAAA-GAGCAGAAGACAGTGGCAATGA-3′ and 5′-
TCATCAATGGTGGTGATGATGATGTTTTTCTCTCTGCACCACTCTTCT-3′. Cycling
parameters for 1st round PCR were 94°C for 2 min followed by 40 cycles of 94°C 30 sec,
annealing temperature of 55-65°C for 45 s, 68°C 4 min, and a final extension at 68°C for 10
min, where the annealing temperature was 65°C for the first 3 cycles, 60°C for the next 11
cycles, and 55°C for the final 26 cycles. 3 μl of product from first-round was used as the
template for the second-round of PCR. Cycling conditions for the second round PCR were
94°C for 2 min followed by 40 cycles of 94°C 30 sec, annealing temperature of 53-55°C for
45 sec, 68°C 2 min and 30 sec, and a final extension at 68°C for 10 min, where annealing
temperature was 53°C for the first 9 cycles and 55°C for the next 31 cycles. Following the
second-round PCR amplification, 0.5 μl Taq polymerase was added to each 50 μl reaction
and an additional 72°C extension for 15 min was performed to add 3′ A overhangs for use in
cloning. Gel purified PCR amplicons were ligated into pCR4-TOPO (Invitrogen) following
the manufacturer’s instructions and transformed into One Shot TOP10 (Invitrogen) cells.
Individual colonies were sequenced using M13F and M13R primers.
Sequence Alignments and Mutation Analysis
Forward and reverse sequence reads from individual samples were assembled using
Geneious Pro software version 5.5.6 (Biomatters Ltd) aligned to gp120YU2 (accession
number M93258). Env sequences containing frameshift mutations or large deletions were
excluded from further analysis. All sequences were analyzed for mutations relative to
gp120YU2 using the Los Alamos Highlighter tool (http://www.hiv.lanl.gov/content/
sequence/HIGHLIGHT/HIGHLIGHTXyPLOT/highlighter.html). and mutations were
numbered using HXBc2 numbering as determined by the Los Alamos Sequence Locator
tool (http://www.hiv.lanl.gov/content/sequence/LOCATE/locate.html). Mutations were
considered recurrent when substitutions within a range of 3 amino acids occurred in the
majority of gp120 clones in more than one mouse. The fidelity of the combined reverse
transcription and nested PCR reactions was determined by amplifying monoclonal wild-type
HIV-1YU2 by the same amplification procedures and identifying RT and PCR induced
mutations (Supplementary Fig. 4).
Generation of HIV-1YU2 envelope mutants
Single, double and triple mutations were introduced into wildtype HIV-1YU2 envelope by
site-directed mutagenesis using QuikChange (Multi-) Site-Directed Mutagenesis Kit
(Agilent Technologies) according to the manufacturer’s specifications.
Statistical analysis
Krustal-Wallis-test with Dunn-multiple comparison or Mann-Whitney U post-hoc tests were
performed using GraphPad Prism version 5.0b for Mac OS X, GraphPad Software, San
Diego California USA, for comparisons of the viral load levels among different antibody
treatment groups and control group (Fig. 1c, Supplementary Fig. 10) and for comparing
gp120 mutation rates (Supplementary Fig. 4). Levels of significance are indicated by
asterisks (*, p≤0.05; **, p≤0.01, ***, p≤0.001). Correlation between viral load (RNA
copies/ml) and absolute numbers of CD4+ T cells in peripheral blood (Supplementary Fig.
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2b) was analyzed by Spearman correlation coefficient (rho) using GraphPad Prism version
5.0b for Mac OS X. An unpaired student’s t-test was used to compare CD4+/CD8+ ratios of
pre-infected mice in control and penta-mix group (Supplementary Fig. 3).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Monotherapy using broadly neutralizing antibodies in HIV-1YU2-infected hu-mice
a, Left panel shows viral loads (RNA copies/ml, y-axis) measured over time (days, x-axis) in
untreated HIV-1YU2-infected hu-mice (control group). Each line represents a single mouse
and symbols reflect viral load measurements. Symbol characters correspond to individual
mice as indicated (right). Hu-mice were infected with HIV-1YU2 (i.p.) between day −22 and
−16 (orange square) and baseline viral loads were measured between day −4 and −2
(Supplementary Table 1). Dotted line represents limit of detection for viral load
determination (800 copies/ml). Right panel shows changes in log10 (RNA copies/ml) from
baseline (grey line) at day 0 with green line representing the average in viral load changes.
b, Illustration of HIV-1 viral loads as in (a) but with single antibody treatment (shaded in
grey) starting at day 0. Red line represents the average in viral load changes superimposed
with averages of the control group (green line, a). c, Changes in log10 (RNA copies/ml) 6-7
days and 27-32 days after treatment initiation. Columns and error bars represent mean and
standard deviation (SD), respectively. Significant statistical differences among groups were
determined by performing a Kruskal-Wallis-test with Dunn-multiple comparison post-hoc
test using GraphPad Prism version 5.0b for Mac OS X, GraphPad Software, San Diego
California, USA. Significant differences among groups were detected at day 6-7 but not at
the later time point (27-32 days). Asterisks (*, p≤0.05; **, p≤0.01) indicate a significant
difference compared to the control group. d, Sequence analysis of HIV-1 gp120 after viral
rebound while on therapy with single bNAbs (Supplementary Fig. 7). Pie charts show the
dsitribution of amino acid changes at the antibodies’ respective target sites. A selection of
amino acid substitutions was tested in vitro and confirmed antibody escape (Supplementary
Fig. 8 and Table 2b). Mutations are relative to HIV-1YU2 and numbered according to
HXBc2. Total number of analyzed mice/gp120 sequences is indicated in the center of the
charts (Supplementary Fig. 7, Supplementary Table 2b).
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Figure 2. HIV therapy by a combination of three (tri-mix) or five (penta-mix) broadly
neutralizing antibodies in HIV-1YU2-infected hu-mice
a, Left panel shows viral loads (RNA copies/ml, y-axis) over time (days, x-axis) in
HIV-1YU2-infected hu-mice treated with a combination of 3BC176, PG16 and 45-46G54W
(tri-mix; grey shading). Each line represents a single mouse and symbols indicate viral load
measurements (Supplementary Table 1). Infection and viral load determination was
performed as in Fig. 1. Right panel shows changes in log10 (RNA copies/ml) from baseline
at day 0. Red and green lines represent the average values in viral load change of tri-mix and
control group (Fig. 1a), respectively. b, Individual gp120 envelope sequences cloned from
single mice (y-axis) during tri-mix therapy after viral rebound. gp120 sequences are
represented by horizontal gray bars with silent mutations indicated in green and amino acid
replacements in red. Black asterisks represent mutations generating a stop codon and bold
gray bars deletions. All mutations are relative to HIV-1YU2 and numbered according to
HXBc2. Mutations at sites highlighted in blue can confer resistance to PG16- or 45-46G54W-
mediated neutralization in vitro (Supplementary Fig. 8, Supplementary Table 3a). c, Pie
charts as in Fig. 1d illustrating distribution of amino acid changes in gp120 (b) at PG16 (left)
or 45-46G54W (right) respective target sites (Supplementary Table 3a). d, As in a, for
HIV-1YU2-infected hu-mice treated with a combination of 3BC176, PG16, 45-46G54W,
PGT128 and 10-1074 (penta-mix; grey shading).
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Figure 3. Viral rebound in HIV-1YU2-infected hu-mice after cessation of antibody therapy
Viral load in RNA copies/ml (blue, left y-axis) and antibody concentration reactive to YU2
gp120 in μg/ml (orange, right y-axis) over time (x-axis) after the last antibody injection (day
0). Green dotted line indicates the viral load average of the control group (Fig. 1a). a, Viral
load and YU2 gp120–reactive antibody concentration after stopping tri-mix therapy in mice
that effectively controlled viremia below limit of detection. b, gp120 sequences illustrated as
in Fig. 2b for viruses obtained after viral rebound from mice previously treated with tri-mix
therapy. Vertical blue bars highlight sites in which mutations are able to confer resistance
(Supplementary Fig. 2b, 3a). c, Viral load and YU2 gp120–reactive antibody concentration
after stopping penta-mix therapy (Supplementary Fig. 3b). d, gp120 sequences for viruses
obtained after rebound from mice previously treated with penta-mix therapy. e, Viral load of
four mice re-treated with penta-mix therapy after viral rebound (c). Treatment period is
highlighted in grey. Mouse numbers correspond to the mice in c.
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